STEK 最新10-Q变化
将 STEK 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-06-22
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +18 | −15 | ~7 | 25 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
In February 2026, the Company launched the Stemtech BioSciences e-commerce retail platform. This platform is intended to expand the Company's retail distribution channels beyond its traditional network marketing model and increase direct consumer access to the Company's products. Management expects …
Commission expense decreased by $72,456, or 59.8%, from $121,210 for the three months ended June 30, 2025 to $48,754 for the three months ended June 30, 2026. The decrease was primarily attributable to a shift in revenue mix during the quarter. During the three months ended June 30, 2026, the Compan…
General and administrative expenses decreased by $158,268 from $697,987 to $539,719. This reduction reflects management's ongoing cost management initiatives, including reductions in personnel costs, professional fees, and overhead.
During the three months ended June 30, 2026 and 2025, total non-operating expense (income) was $(166,791) and $4,708, respectively. Interest expense increased to $112,734 for the three months ended June 30, 2026, from $79,727 for the same period in 2025. During the three months ended June 30, 2026, …
Interest expense for the three months ended June 30, 2026 was $112,734, compared to $79,727 for the same period in 2025.
相对上期删除的文字 · 来源:10-Q · 2026-06-22
Commission expense decreased by $140,619, from $185,558 to $44,939, primarily as a direct consequence of the decline in net sales, as commissions are largely variable and paid as a percentage of revenue generated by the Company’s independent distributor network.
General and administrative expenses decreased by $328,450 from $1,727,367 to $1,398,917. This reduction reflects management’s ongoing cost management initiatives, including reductions in personnel costs, professional fees, and overhead, partially offset by stock-based compensation expense of $101,06…
During the three months ended March 31, 2026 and 2025, total non-operating expenses were $158,631 and $253,821, respectively, reflecting a decrease of $90,798.
Interest expense decreased significantly to $97,659 for the three months ended March 31, 2026, from $245,368 for the same period in 2025, a reduction of $147,709. This decrease reflects the partial extinguishment of outstanding convertible debt through equity conversions completed during the quarter…
Our net loss for the three months ended March 31, 2026 was $1,252,880, compared to a net loss of $1,458,726 for the same period in 2025. Despite a significant decline in net sales, the net loss improved by $205,846, or 14.1%, period over period. This improvement was primarily driven by a reduction i…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议